ClinicalTrials.gg
RecruitingNCT05332782PRIME-MRUpdated Apr 18, 2022

Outcomes of Patients tReated wIth Mitral Transcatheter Edge-to-edge Repair for Primary Mitral Regurgitation Registry

An observational study in Mitral Regurgitation, sponsored by Universitätsklinikum Hamburg-Eppendorf. Recruiting at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-18.

Sponsored by Universitätsklinikum Hamburg-Eppendorf · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Mitral Valve Insufficiency with a site in France — 17 open to participants now, 21 under way, none of them phase 3. Mitral Valve Insufficiency · France.

Planned enrollment
Largest of 16
2,000 · median 470
Started
2022
with 1 other
Observational
16 of 42
10 open now
Primary completion
2025-01
later than 5 of 20 live
Registered
35th of 42
by date
Lead sponsor
2 of 42
Universitätsklinikum Hamburg-Eppendorf

Among the 42 studies in Mitral Valve Insufficiency with a site in France, this one has the largest planned enrollment of the 16 observational ones that give a count, is one of 2 that started in 2022, is one of 16 observational ones, reaches primary completion later than 5 of the 20 other live ones, and was the 35th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

17 of the 42 studies in Mitral Valve Insufficiency with a site in France are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Mitral Valve Insufficiency with a site in France, or all of them as a file.
02

Study summary

This multinational, non-interventional, investigator-initiated, retrospective study aims to investigate outcomes of patients, who underwent mitral valve transcatheter edge-to-edge repair (M-TEER) for primary mitral regurgitation (PMR).

03

Conditions studied

  • Mitral Regurgitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive patients undergoing transcatheter edge-to-edge repair for primary mitral regurgitation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • primary mitral regurgitation
  • patient underwent M-TEER
  • echocardiography data at baseline, procedure and follow-up
  • follow-up of at least 12 months

Exclusion criteria

Exclusion Criteria

  • age under 18 years
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • M-TEER

    Patients with primary mitral regurgitation undergoing mitral valve transcatheter edge-to-edge repair.

06

What researchers measure

Primary outcomes

  1. All-cause mortality

    Incidence of death from any cause.

    Time frame: 12 months

  2. Cardiovascular mortality

    Incidence of cardiovascular death, defined as death attributable to myocardial ischemia and infarction, heart failure, cardiac arrest because of other or unknown cause, or cerebrovascular accident.

    Time frame: 12 months

  3. Rehospitalization for congestive heart failure

    Incidence of new-onset or worsening signs and symptoms of heart failure that required urgent therapy and resulted in hospitalization, e.g. as assessed by patient interviews or medical records.

    Time frame: 12 months

  4. Re-do mitral valve procedure

    Incidence of unplanned surgical (mitral valve repair or replacement) or transcatheter re-intervention (re-do transcatheter edge-to-edge repair), e.g. as assessed by patient interviews or medical records.

    Time frame: 12 months

Secondary outcomes

  1. Residual mitral regurgitation

    Mitral regurgitation severity (0, 1+, 2+, 3+, 4+) as assessed by transthoracic echocardiography at discharge.

    Time frame: up to 30 days

  2. Residual mitral regurgitation

    Mitral regurgitation severity (0, 1+, 2+, 3+, 4+) as assessed by transthoracic echocardiography at 1-year follow-up.

    Time frame: 12 months

  3. MVARC (Mitral Valve Academic Research Consortium) Technical success

    All of the following must be present: 1. Absence of procedural mortality 2. Successful access, delivery, and retrieval 3. Successful deployment and correct positioning of the first device 4. Freedom from emergency surgery or reintervention related to the device or access procedure

    Time frame: 1 day (at exit from the catheterization laboratory)

  4. Functional success

    If one of the following is present: 1. Residual mitral regurgitation ≤2+ 2. Effective regurgitant orifice area ≤15 mm2 3. Transmitral gradient \<5 mmHg

    Time frame: 1 day (at exit from the catheterization laboratory)

07

Study locations

6 of 6 sites recruiting
  • Montefiore Medical Center
    New York, New York 10467, United States
    Recruiting
    • Azeem Latib, MD · Contact
    • Andrea Scotti, MD · Contact
  • Centre Hospitalier de Bordeaux
    Bordeaux, France
    Recruiting
    • Thomas Modine, MD, PhD · Contact
  • Université Lille, Inserm, Centre Hospitalier Universitaire de Lille
    Lille, France
    Recruiting
    • Augustin Coisne, MD · Contact
  • University Hospital of Rennes, Centre Hospitalier de Rennes
    Rennes, France
    Recruiting
    • Erwan Donal, MD · Contact
  • University Heart & Vascular Center Hamburg
    Hamburg, 20246, Germany
    Recruiting
    • Benedikt Koell, MD · Contactb.koell@uke.de · +4915222815230
    • Sebastian Ludwig, MD · Contact
    • Daniel Kalbacher, MD · Principal investigator
  • Klinikum der Universität München
    Munich, Germany
    Recruiting
    • Jörg Hausleiter, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2022 (actual). Primary completion is estimated for Jan 2025, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2022
First posted
Apr 18, 2022
StartActual
Mar 1, 2022
Primary completionEst.
Jan 1, 2025
CompletionEst.
Jan 1, 2026
Last update
Apr 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05332782
Responsible party
Sponsor
First posted
Apr 18, 2022
Start date
Mar 1, 2022
Primary completion
Jan 1, 2025 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Apr 18, 2022

Study contacts

Benedikt Koell, MD
Contact
b.koell@uke.de
+4915222815230
Sebastian Ludwig, MD
Contact
se.ludwig@uke.de
+491522816168
Daniel Kalbacher, MD
principal investigator · University Heart & Vascular Center Hamburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion